Current Management of Ventricular Tachycardia: Approaches and Timing

Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effec...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Roy M. John, MBBS, PhD [verfasserIn] William Stevenson, MD [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2016

Schlagwörter:	ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia

Übergeordnetes Werk:	In: Cardiovascular Innovations and Applications - Compuscript, 2017, 1(2016), 2, Seite 131-142
Übergeordnetes Werk:	volume:1 ; year:2016 ; number:2 ; pages:131-142

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.15212/CVIA.2015.0015

Katalog-ID:	DOAJ056222890

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ056222890
003	DE-627
005	20230503023847.0
007	cr uuu---uuuuu
008	230227s2016 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.15212/CVIA.2015.0015 \|2 doi
035			\|a (DE-627)DOAJ056222890
035			\|a (DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC666-701
100	0		\|a Roy M. John, MBBS, PhD \|e verfasserin \|4 aut
245	1	0	\|a Current Management of Ventricular Tachycardia: Approaches and Timing
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy.
650		4	\|a ventricular tachycardia
650		4	\|a ablation
650		4	\|a idiopathic ventricular tachycardia
650		4	\|a polymorphic ventricular tachycardia
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a William Stevenson, MD \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cardiovascular Innovations and Applications \|d Compuscript, 2017 \|g 1(2016), 2, Seite 131-142 \|w (DE-627)1696242681 \|x 20098782 \|7 nnns
773	1	8	\|g volume:1 \|g year:2016 \|g number:2 \|g pages:131-142
856	4	0	\|u https://doi.org/10.15212/CVIA.2015.0015 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94 \|z kostenfrei
856	4	0	\|u http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2009-8618 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2009-8782 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 1 \|j 2016 \|e 2 \|h 131-142

Indexfelder

author_variant	m j m p r mjmp mjmpr s m w sm smw
matchkey_str	article:20098782:2016----::urnmngmnovnrclrahcriap
hierarchy_sort_str	2016
callnumber-subject-code	RC
publishDate	2016
allfields	10.15212/CVIA.2015.0015 doi (DE-627)DOAJ056222890 (DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94 DE-627 ger DE-627 rakwb eng RC666-701 Roy M. John, MBBS, PhD verfasserin aut Current Management of Ventricular Tachycardia: Approaches and Timing 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy. ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia Diseases of the circulatory (Cardiovascular) system William Stevenson, MD verfasserin aut In Cardiovascular Innovations and Applications Compuscript, 2017 1(2016), 2, Seite 131-142 (DE-627)1696242681 20098782 nnns volume:1 year:2016 number:2 pages:131-142 https://doi.org/10.15212/CVIA.2015.0015 kostenfrei https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94 kostenfrei http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002 kostenfrei https://doaj.org/toc/2009-8618 Journal toc kostenfrei https://doaj.org/toc/2009-8782 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2016 2 131-142
spelling	10.15212/CVIA.2015.0015 doi (DE-627)DOAJ056222890 (DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94 DE-627 ger DE-627 rakwb eng RC666-701 Roy M. John, MBBS, PhD verfasserin aut Current Management of Ventricular Tachycardia: Approaches and Timing 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy. ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia Diseases of the circulatory (Cardiovascular) system William Stevenson, MD verfasserin aut In Cardiovascular Innovations and Applications Compuscript, 2017 1(2016), 2, Seite 131-142 (DE-627)1696242681 20098782 nnns volume:1 year:2016 number:2 pages:131-142 https://doi.org/10.15212/CVIA.2015.0015 kostenfrei https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94 kostenfrei http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002 kostenfrei https://doaj.org/toc/2009-8618 Journal toc kostenfrei https://doaj.org/toc/2009-8782 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2016 2 131-142
allfields_unstemmed	10.15212/CVIA.2015.0015 doi (DE-627)DOAJ056222890 (DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94 DE-627 ger DE-627 rakwb eng RC666-701 Roy M. John, MBBS, PhD verfasserin aut Current Management of Ventricular Tachycardia: Approaches and Timing 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy. ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia Diseases of the circulatory (Cardiovascular) system William Stevenson, MD verfasserin aut In Cardiovascular Innovations and Applications Compuscript, 2017 1(2016), 2, Seite 131-142 (DE-627)1696242681 20098782 nnns volume:1 year:2016 number:2 pages:131-142 https://doi.org/10.15212/CVIA.2015.0015 kostenfrei https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94 kostenfrei http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002 kostenfrei https://doaj.org/toc/2009-8618 Journal toc kostenfrei https://doaj.org/toc/2009-8782 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2016 2 131-142
allfieldsGer	10.15212/CVIA.2015.0015 doi (DE-627)DOAJ056222890 (DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94 DE-627 ger DE-627 rakwb eng RC666-701 Roy M. John, MBBS, PhD verfasserin aut Current Management of Ventricular Tachycardia: Approaches and Timing 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy. ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia Diseases of the circulatory (Cardiovascular) system William Stevenson, MD verfasserin aut In Cardiovascular Innovations and Applications Compuscript, 2017 1(2016), 2, Seite 131-142 (DE-627)1696242681 20098782 nnns volume:1 year:2016 number:2 pages:131-142 https://doi.org/10.15212/CVIA.2015.0015 kostenfrei https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94 kostenfrei http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002 kostenfrei https://doaj.org/toc/2009-8618 Journal toc kostenfrei https://doaj.org/toc/2009-8782 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2016 2 131-142
allfieldsSound	10.15212/CVIA.2015.0015 doi (DE-627)DOAJ056222890 (DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94 DE-627 ger DE-627 rakwb eng RC666-701 Roy M. John, MBBS, PhD verfasserin aut Current Management of Ventricular Tachycardia: Approaches and Timing 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy. ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia Diseases of the circulatory (Cardiovascular) system William Stevenson, MD verfasserin aut In Cardiovascular Innovations and Applications Compuscript, 2017 1(2016), 2, Seite 131-142 (DE-627)1696242681 20098782 nnns volume:1 year:2016 number:2 pages:131-142 https://doi.org/10.15212/CVIA.2015.0015 kostenfrei https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94 kostenfrei http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002 kostenfrei https://doaj.org/toc/2009-8618 Journal toc kostenfrei https://doaj.org/toc/2009-8782 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2016 2 131-142
language	English
source	In Cardiovascular Innovations and Applications 1(2016), 2, Seite 131-142 volume:1 year:2016 number:2 pages:131-142
sourceStr	In Cardiovascular Innovations and Applications 1(2016), 2, Seite 131-142 volume:1 year:2016 number:2 pages:131-142
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Cardiovascular Innovations and Applications
authorswithroles_txt_mv	Roy M. John, MBBS, PhD @@aut@@ William Stevenson, MD @@aut@@
publishDateDaySort_date	2016-01-01T00:00:00Z
hierarchy_top_id	1696242681
id	DOAJ056222890
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ056222890</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503023847.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15212/CVIA.2015.0015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ056222890</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Roy M. John, MBBS, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current Management of Ventricular Tachycardia: Approaches and Timing</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ventricular tachycardia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ablation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">idiopathic ventricular tachycardia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">polymorphic ventricular tachycardia</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Stevenson, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cardiovascular Innovations and Applications</subfield><subfield code="d">Compuscript, 2017</subfield><subfield code="g">1(2016), 2, Seite 131-142</subfield><subfield code="w">(DE-627)1696242681</subfield><subfield code="x">20098782</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:131-142</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15212/CVIA.2015.0015</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2009-8618</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2009-8782</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2016</subfield><subfield code="e">2</subfield><subfield code="h">131-142</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Roy M. John, MBBS, PhD
spellingShingle	Roy M. John, MBBS, PhD misc RC666-701 misc ventricular tachycardia misc ablation misc idiopathic ventricular tachycardia misc polymorphic ventricular tachycardia misc Diseases of the circulatory (Cardiovascular) system Current Management of Ventricular Tachycardia: Approaches and Timing
authorStr	Roy M. John, MBBS, PhD
ppnlink_with_tag_str_mv	@@773@@(DE-627)1696242681
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	20098782
topic_title	RC666-701 Current Management of Ventricular Tachycardia: Approaches and Timing ventricular tachycardia ablation idiopathic ventricular tachycardia polymorphic ventricular tachycardia
topic	misc RC666-701 misc ventricular tachycardia misc ablation misc idiopathic ventricular tachycardia misc polymorphic ventricular tachycardia misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc ventricular tachycardia misc ablation misc idiopathic ventricular tachycardia misc polymorphic ventricular tachycardia misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc ventricular tachycardia misc ablation misc idiopathic ventricular tachycardia misc polymorphic ventricular tachycardia misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cardiovascular Innovations and Applications
hierarchy_parent_id	1696242681
hierarchy_top_title	Cardiovascular Innovations and Applications
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1696242681
title	Current Management of Ventricular Tachycardia: Approaches and Timing
ctrlnum	(DE-627)DOAJ056222890 (DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94
title_full	Current Management of Ventricular Tachycardia: Approaches and Timing
author_sort	Roy M. John, MBBS, PhD
journal	Cardiovascular Innovations and Applications
journalStr	Cardiovascular Innovations and Applications
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2016
contenttype_str_mv	txt
container_start_page	131
author_browse	Roy M. John, MBBS, PhD William Stevenson, MD
container_volume	1
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	Roy M. John, MBBS, PhD
doi_str_mv	10.15212/CVIA.2015.0015
author2-role	verfasserin
title_sort	current management of ventricular tachycardia: approaches and timing
callnumber	RC666-701
title_auth	Current Management of Ventricular Tachycardia: Approaches and Timing
abstract	Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy.
abstractGer	Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy.
abstract_unstemmed	Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Current Management of Ventricular Tachycardia: Approaches and Timing
url	https://doi.org/10.15212/CVIA.2015.0015 https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94 http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002 https://doaj.org/toc/2009-8618 https://doaj.org/toc/2009-8782
remote_bool	true
author2	William Stevenson, MD
author2Str	William Stevenson, MD
ppnlink	1696242681
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.15212/CVIA.2015.0015
callnumber-a	RC666-701
up_date	2024-07-03T19:35:30.877Z
_version_	1803587767113875456
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ056222890</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503023847.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15212/CVIA.2015.0015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ056222890</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJca37f35ed1d347b392b62f99bf5f2d94</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Roy M. John, MBBS, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current Management of Ventricular Tachycardia: Approaches and Timing</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ventricular tachycardia (VT) in the presence of structural heart disease is associated with sudden cardiac death and warrants prompt attention. Implantable cardioverter defibrillators (ICDs) while highly effective in terminating sustained ventricular arrhythmias and reducing mortality, have no effect on the arrhythmia substrate and recurrent shocks for VT termination occur in approximately 20% of patients. Shocks worsen quality of life and are associated with progression of heart failure and increased mortality. Antiarrhythmic drugs, mainly in the form of beta-blockers or amiodarone, are moderately effective in reducing ICD therapies but drug intolerance and serious toxicities of amiodarone necessitate drug cessation in a quarter of patients. Catheter ablation has emerged as an effective treatment for control of frequent VT episodes and can be life saving in cases of incessant VT or VT storm. As experience increases, it is being used increasingly earlier, rather than a last resort therapy. Efficacy varies with the nature of the underlying heart disease. Intramural arrhythmia substrate and failure to create permanent ablation lesions remain challenges and repeat procedures are necessary in a third to a half of patients. For idiopathic VTs or PVCs that are symptomatic or worsen LV function, catheter ablation is often an effective therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ventricular tachycardia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ablation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">idiopathic ventricular tachycardia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">polymorphic ventricular tachycardia</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Stevenson, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cardiovascular Innovations and Applications</subfield><subfield code="d">Compuscript, 2017</subfield><subfield code="g">1(2016), 2, Seite 131-142</subfield><subfield code="w">(DE-627)1696242681</subfield><subfield code="x">20098782</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:131-142</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15212/CVIA.2015.0015</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ca37f35ed1d347b392b62f99bf5f2d94</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2009-8618</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2009-8782</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2016</subfield><subfield code="e">2</subfield><subfield code="h">131-142</subfield></datafield></record></collection>
score	7.3974285

Nicht das Richtige dabei?

Schreiben Sie uns!

Current Management of Ventricular Tachycardia: Approaches and Timing

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?